CEDAR KNOLLS, N.J.,
July 12, 2017 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), announced today that it will be a sponsor at this
year's IDEA World Convention in Las
Vegas to "put its money where its mouth is" with a 90-day
money back guarantee on their Qurr Fortetopin® line of
muscle health products. MYOS is assuring customers that they
will see results in 90 days using Qurr Fortetropin® powders or
shakes in conjunction with resistance training– or they can get
their money back.
"We are pleased to be a sponsor at the IDEA World Convention,
which has set the standard for the fitness/wellness industry for
over 35 years," said Joseph Mannello, CEO. IDEA provides
education, program evaluation, trends and research to a
250,000-member data base of credentialed trainers, program/fitness
directors, business owners, and nutrition professionals. "This is
an excellent venue for MYOS to introduce Qurr Fortetropin® to the
professional wellness and fitness community," Mr. Mannello continued. Qurr
Fortetropin® is MYOS' proprietary ingredient that naturally reduces
myostatin and which has been clinically shown to build lean muscle
mass and improve muscle function.
The 90-Day Qurr® Challenge guarantee is simple: the
consumer takes the product daily for 90 days in conjunction with
resistance training twice per week, and should be able to observe
improvements in muscle health (this could translate into more
muscle definition, being more toned, or gains in strength).
If not satisfied, the consumer should send us before-and-after
pictures with a brief description of their experience while on the
product. If the consumer follows these instructions and does
not get the benefit(s) described, MYOS will refund the full
purchase price (details: https://qurr.com/challenge).
The Qurr® line of muscle health products will be on display in
Booth #1841 at the Las Vegas IDEA World Convention July 19-23.
About MYOS RENS Technology Inc.
MYOS RENS Technology
(MYOS), "The Muscle Company™", is a Cedar
Knolls, NJ-based biotherapeutics and bionutrition company
focused on developing products that improve muscle health and
performance and bringing them to market. MYOS is the owner of
Fortetropin®, the world's first clinically demonstrated
myostatin reducer. Myostatin is a natural regulatory protein, which
inhibits muscle growth and recovery. Fortetropin® is
manufactured to optimize biological activity, which MYOS believes
has the potential to redefine existing standards of physical health
and wellness enhancement.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful launch of our
products, including Qurr® products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into
partnership opportunities, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Media Contact
MYOS RENS Technology Inc.
Joanne Goodford
973-509-0444
jgoodford@myoscorp.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-to-introduce-the-qurr-line-of-muscle-health-products-at-35th-idea-world-convention-july-19-23-2017-in-las-vegas-300486692.html
SOURCE MYOS RENS Technology